KR20230110538A - 트라이아진 다이온 유도체, 이의 제조 방법 및 의약에서 이의 용도 - Google Patents
트라이아진 다이온 유도체, 이의 제조 방법 및 의약에서 이의 용도 Download PDFInfo
- Publication number
- KR20230110538A KR20230110538A KR1020237019549A KR20237019549A KR20230110538A KR 20230110538 A KR20230110538 A KR 20230110538A KR 1020237019549 A KR1020237019549 A KR 1020237019549A KR 20237019549 A KR20237019549 A KR 20237019549A KR 20230110538 A KR20230110538 A KR 20230110538A
- Authority
- KR
- South Korea
- Prior art keywords
- group
- formula
- compound
- alkyl
- membered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/40—Nitrogen atoms
- C07D251/42—One nitrogen atom
- C07D251/46—One nitrogen atom with oxygen or sulfur atoms attached to the two other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011310827 | 2020-11-20 | ||
| CN202011310827.4 | 2020-11-20 | ||
| CN202110021509 | 2021-01-08 | ||
| CN202110021509.4 | 2021-01-08 | ||
| CN202110244090.9 | 2021-03-05 | ||
| CN202110244090 | 2021-03-05 | ||
| CN202110464375.3 | 2021-04-28 | ||
| CN202110464375 | 2021-04-28 | ||
| PCT/CN2021/131642 WO2022105852A1 (zh) | 2020-11-20 | 2021-11-19 | 三嗪二酮类衍生物、其制备方法及其在医药上的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20230110538A true KR20230110538A (ko) | 2023-07-24 |
Family
ID=81708401
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237019549A Pending KR20230110538A (ko) | 2020-11-20 | 2021-11-19 | 트라이아진 다이온 유도체, 이의 제조 방법 및 의약에서 이의 용도 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240010639A1 (https=) |
| EP (1) | EP4249474A4 (https=) |
| JP (1) | JP7849587B2 (https=) |
| KR (1) | KR20230110538A (https=) |
| CN (4) | CN119638682A (https=) |
| AU (1) | AU2021381664A1 (https=) |
| CA (1) | CA3198934A1 (https=) |
| MX (1) | MX2023005533A (https=) |
| TW (1) | TW202227420A (https=) |
| WO (1) | WO2022105852A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA53491A (fr) | 2018-08-31 | 2021-09-15 | Cytokinetics Inc | Inhibiteurs de sarcomes cardiaques |
| CN117083275A (zh) | 2021-03-04 | 2023-11-17 | 赛特凯恩蒂克公司 | 心脏肌节抑制剂 |
| CA3211730A1 (en) * | 2021-03-17 | 2022-09-22 | Hugh Y. Zhu | Nitrogen-containing heterocyclic ketones, preparation methods and medicinal uses thereof |
| PT4370116T (pt) | 2021-07-16 | 2025-03-14 | Cytokinetics Inc | Regimes de administração de aficamten para o tratamento da cardiomiopatia hipertrófica obstrutiva |
| CN117088854A (zh) * | 2022-05-20 | 2023-11-21 | 江苏恒瑞医药股份有限公司 | 一种三嗪二酮类衍生物的可药用盐、晶型及制备方法 |
| CN119053591A (zh) * | 2022-05-20 | 2024-11-29 | 江苏恒瑞医药股份有限公司 | 一种三嗪二酮类衍生物的晶型及制备方法 |
| WO2024056096A1 (zh) * | 2022-09-16 | 2024-03-21 | 江苏豪森药业集团有限公司 | 一种含氮杂环酮化合物的晶型及其制备方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010040661A1 (en) | 2008-10-09 | 2010-04-15 | F. Hoffmann-La Roche Ag | Modulators for amyloid beta |
| PL2399910T3 (pl) * | 2009-02-13 | 2014-09-30 | Shionogi & Co | Pochodne triazyny jako antagoniści receptora p2x3 i/albo p2x2/3 i kompozycja farmaceutyczna zawierająca je |
| WO2012006004A1 (en) * | 2010-06-28 | 2012-01-12 | Janssen Pharmaceutica Nv | Prokineticin 1 receptor antagonists for the treatment of pain |
| CN103153968B (zh) | 2010-08-10 | 2016-02-03 | 盐野义制药株式会社 | 三唑衍生物及含有其的具有镇痛作用的药物组合物 |
| SMT202000071T1 (it) * | 2013-06-21 | 2020-03-13 | Myokardia Inc | Composti di pirimidinadione contro le condizioni cardiache |
| US9199945B2 (en) * | 2013-06-21 | 2015-12-01 | MyoKardia, Inc. | Cycloalkyl-substituted pyrimidinedione compounds |
| US9663516B2 (en) * | 2014-12-18 | 2017-05-30 | MyoKardia, Inc. | Bicyclic-pyrimidinedione compounds |
| ES2975263T3 (es) | 2016-06-20 | 2024-07-04 | Novartis Ag | Formas cristalinas de un compuesto triazolopirimidínico |
| RS65492B1 (sr) | 2017-07-24 | 2024-05-31 | Novartis Ag | Jedinjenja i kompozicije za lečenje stanja povezanih sa aktivnošću nlrp |
| CA3071948A1 (en) | 2017-08-04 | 2019-02-07 | MyoKardia, Inc. | Mavacamten for use in the treatment of hypertrophic cardiomyopathy |
| CN111094300B (zh) * | 2018-01-31 | 2022-09-16 | 江苏恒瑞医药股份有限公司 | 苯并杂芳基类衍生物、其制备方法及其在医药上的应用 |
| MA53491A (fr) * | 2018-08-31 | 2021-09-15 | Cytokinetics Inc | Inhibiteurs de sarcomes cardiaques |
| EA202191152A1 (ru) | 2018-10-29 | 2022-01-19 | Миокардиа, Инк. | Тетрагидропиран (thp)-замещенные бициклические соединения пиримидиндиона |
| CN111116492B (zh) * | 2019-01-25 | 2021-07-09 | 青岛吉澳医药科技有限公司 | 氘代苯甲氨嘧啶二酮衍生物及其用途 |
| CN110698415B (zh) | 2019-10-21 | 2023-05-09 | 上海先行医药开发有限公司 | 一种肌球蛋白抑制剂及其制备方法和用途 |
| CA3211730A1 (en) * | 2021-03-17 | 2022-09-22 | Hugh Y. Zhu | Nitrogen-containing heterocyclic ketones, preparation methods and medicinal uses thereof |
-
2021
- 2021-11-19 WO PCT/CN2021/131642 patent/WO2022105852A1/zh not_active Ceased
- 2021-11-19 AU AU2021381664A patent/AU2021381664A1/en active Pending
- 2021-11-19 CN CN202411649482.3A patent/CN119638682A/zh active Pending
- 2021-11-19 CN CN202411649280.9A patent/CN119638680A/zh active Pending
- 2021-11-19 EP EP21893999.9A patent/EP4249474A4/en active Pending
- 2021-11-19 CN CN202180065655.5A patent/CN116323598B/zh active Active
- 2021-11-19 CA CA3198934A patent/CA3198934A1/en active Pending
- 2021-11-19 MX MX2023005533A patent/MX2023005533A/es unknown
- 2021-11-19 US US18/253,704 patent/US20240010639A1/en active Pending
- 2021-11-19 TW TW110143208A patent/TW202227420A/zh unknown
- 2021-11-19 KR KR1020237019549A patent/KR20230110538A/ko active Pending
- 2021-11-19 JP JP2023530323A patent/JP7849587B2/ja active Active
- 2021-11-19 CN CN202411649375.0A patent/CN119638681A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN116323598A (zh) | 2023-06-23 |
| CN119638680A (zh) | 2025-03-18 |
| CN119638681A (zh) | 2025-03-18 |
| CN116323598B (zh) | 2024-11-15 |
| WO2022105852A1 (zh) | 2022-05-27 |
| CA3198934A1 (en) | 2022-05-27 |
| TW202227420A (zh) | 2022-07-16 |
| AU2021381664A1 (en) | 2023-06-15 |
| US20240010639A1 (en) | 2024-01-11 |
| MX2023005533A (es) | 2023-05-25 |
| JP7849587B2 (ja) | 2026-04-22 |
| EP4249474A4 (en) | 2024-04-17 |
| EP4249474A1 (en) | 2023-09-27 |
| JP2023550444A (ja) | 2023-12-01 |
| CN119638682A (zh) | 2025-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20230110538A (ko) | 트라이아진 다이온 유도체, 이의 제조 방법 및 의약에서 이의 용도 | |
| CN114149423B (zh) | 四氢吡啶并嘧啶二酮类衍生物、其制备方法及其在医药上的应用 | |
| CN114539229B (zh) | 嘧啶二酮类衍生物、其制备方法及其在医药上的应用 | |
| CN114516843B (zh) | 嘧啶二酮类衍生物、其制备方法及其在医药上的应用 | |
| KR20210143803A (ko) | Tead 전사인자의 신규한 소분자 저해제 | |
| KR20240046530A (ko) | 설폰아미드 유도체, 이의 제조 방법 및 이의 의학적 용도 | |
| EP3782987A1 (en) | Benzopyrazole compound used as rho kinase inhibitor | |
| WO2019134539A1 (zh) | 二氢吡唑酮并嘧啶类化合物及其制备方法和用途 | |
| CN116507621B (zh) | 嘧啶二酮类衍生物、其制备方法及其在医药上的应用 | |
| KR20150080423A (ko) | 1,2 나프토퀴논 유도체 및 이의 제조방법 | |
| JP2026004421A (ja) | 抗体－薬物複合体に適した毒素分子 | |
| CN114456163B (zh) | 四氢吡啶并嘧啶二酮类衍生物、其制备方法及其在医药上的应用 | |
| CN114539257B (zh) | 嘧啶二酮类螺环衍生物、其制备方法及其在医药上的应用 | |
| CA3203698A1 (en) | 2-pyridone derivative, and preparation method therefor and pharmaceutical application thereof | |
| US20250059206A1 (en) | Fused ring compound acting as shp2 inhibitor | |
| CN114144176A (zh) | 用于抑制fgfr4的化合物 | |
| EA048346B1 (ru) | Производное триазиндионов, способ его получения и его применение в медицине | |
| HK40095559A (zh) | 三嗪二酮类衍生物、其制备方法及其在医药上的应用 | |
| HK40095559B (zh) | 三嗪二酮类衍生物、其制备方法及其在医药上的应用 | |
| CN119039236A (zh) | 一种苄胺嘧啶二酮衍生物及其用途 | |
| WO2025191176A1 (en) | Wrn inhibitory compounds | |
| WO2025193111A1 (en) | An imidazole-indole derivative binding to 5-ht7 serotonin receptor, a pharmaceutical composition comprising the derivative, uses of the derivative and the composition, and an intermediate product for manufacturing the imidazole-indole derivative | |
| WO2006088080A1 (ja) | シクロヘプタ［ｂ］ピリジン－３－カルボニルグアニジン誘導体およびそれを含有する医薬品 | |
| WO2020253872A1 (zh) | 具有a2a腺苷受体激动活性的2-苄叉肼基腺苷类化合物 | |
| JPH11130772A (ja) | 含窒素複素環化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| D21 | Rejection of application intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |